The Role of Appendectomy for Mucinous Ovarian Neoplasms
Tuesday, October 16, 2012
The Role of Appendectomy for Mucinous Ovarian Neoplasms
The Role of Appendectomy for Mucinous Ovarian Neoplasms
To
determine how frequently the appendix harbors pathology in women having
surgery for mucinous neoplasms of the ovary and assess the associated
morbidity.
A
retrospective chart review of patients operated upon at our institution
with the diagnosis of a mucinous neoplasm of the ovary or appendix.
A
total of 327 cases were identified. Of the 309 women with mucinous
ovarian neoplasms, 197 (64%) were benign, 68 (22%) LMP, and 44 (14%)
were invasive. Out of 155 appendectomies performed, only 1 metastatic
low grade mucinous appendiceal tumor was found, but this appendix was
grossly abnormal. There was no association between wound complications
and appendectomy.
When
a grossly normal appendix is removed during surgery for a mucinous
ovarian neoplasm without evidence of pseudomyxoma peritonei, no primary
or metastatic mucinous appendiceal tumors were found.
Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred - (Lynch Syndrome)
Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred Pediatric Blood & Cancer
Abstract
Background
Heterozygous
germline mutations in DNA mismatch repair (MMR) genes cause Lynch
syndrome. Biallelic MMR mutations cause a distinct syndrome
characterized by brain tumors, lymphoid malignancies, and
gastrointestinal cancers during childhood. These children usually
succumb to multiple cancers before adulthood. We developed a
surveillance protocol aiming at early detection for these individuals
and report the 10-year experience with a kindred.
Methods
On
the basis of genetic testing and early age tumors, the kindred started a
cancer surveillance protocol based on the crude estimates of cancer
risks and available cancer screening: imaging, endoscopy, and
hematologic tests.
Results
Over
the 10-year follow-up period, the screening protocol detected 15
tumors. These included three high-grade adenomatous colonic polyps and
two colon cancers. In one child, MRI revealed an asymptomatic anaplastic
astrocytoma which was treated by complete resection and radiation. All
three cancers identified during surveillance were small and asymptomatic
at diagnosis. The two sisters are currently 16 and 18 years of age with
no evidence of malignant disease. Both parents have annual
colonoscopies and the father at 43 years had two colonic adenomatous
polyps.
Conclusions
We report on the long-term outcome in patients with biallelic MMR mutations who benefited from prophylactic cancer surveillance. Genetic screening and subsequent surveillance led to earlier recognition of asymptomatic tumors at stages more amenable to resection and probable cure. Multicenter collaboration and implementation of surveillance guidelines is necessary to further determine genotype–phenotype correlations.Sun exposure and risk of epithelial ovarian cancer.
Sun exposure and risk of epithelial ov... [Cancer Causes Control. 2012] - PubMed - NCBI
Abstract
PURPOSE:
Associations between sun exposure (a primary source of vitamin D) and risk of ovarian cancer have been inconsistent. Furthermore, studies have not investigated whether sun exposure at different periods in the lifetime of a person results in differences in risk associations, and little is known about differences according to histological subtype.METHODS:
Using a population-based case-control study of 1,334 non-Hispanic white women diagnosed with epithelial ovarian cancer in western Washington State between 2002 and 2009 and 1,679 non-Hispanic white controls, we assessed the relation of epithelial ovarian cancer with constitutional pigmentation characteristics, sun exposure behaviors, and an index of ultraviolet (UV) exposure based on residential history. Information was collected through in-person interviews. Logistic regression was used to compute odds ratios, 95 % confidence intervals, and trend p values (P(trend)).RESULTS:
We noted no association with residence-based measures of UV exposure or self-reported sun exposure, either over the lifetime or within specific age intervals. Also, we observed little evidence of association between constitutional pigmentation characteristics and risk, save for a suggestion of increased risk among women who reported increased ability to suntan upon prolonged sun exposure (P(trend) = 0.03).CONCLUSIONS:
Results from this study suggest that sun exposure has little influence on the risk of epithelial ovarian cancer. Additional studies in populations with a wider gradient of sun exposure may yet be warranted.Monday, October 15, 2012
Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum - Full Text View - ClinicalTrials.gov
Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum - Full Text View - ClinicalTrials.gov
| Responsible Party: | ARCAGY/ GINECO GROUP |
| ClinicalTrials.gov Identifier: | NCT01705158 History of Changes |
| Other Study ID Numbers: | MYCA (GINECO-OV220), 2012-001999-10 |
| Study First Received: | October 1, 2012 |
| Last Updated: | October 11, 2012 |
| Health Authority: | France: L’Agence nationale de sécurité du médicament et des produits de santé |
Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab - Full Text View - ClinicalTrials.gov
Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab - Full Text View - ClinicalTrials.gov
| Study Start Date: | October 2012 |
| Estimated Study Completion Date: | December 2015 |
Sunday, October 14, 2012
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer – A study by the OVCAD consortium
View full text
Abstract
Objective
Comparative
proteomics identified the plasma protein afamin as potential biomarker
for ovarian cancer (OC). Significantly decreased afamin plasma
concentrations in pre-therapeutic OC patients reconstituted to control
values after successful tumor surgery. This study evaluates the
association of afamin with survival and response to therapy in serous OC
patients within the OVCAD consortium project.
Methods
We
measured afamin in 215 pre-therapeutic plasma samples, 246 tumor
lysates and 109 plasma samples taken six months after finishing
platinum-based chemotherapy. Differences in afamin plasma concentrations
among FIGO stages were tested by Kruskal Wallis test; association of
afamin concentrations with overall and progression-free survival was
evaluated using Kaplan-Meier survival plots and multivariate adjusted
COX regression analysis.
Results
Pre-therapeutic
afamin correlated significantly with FIGO stages (p = 0.012) and was
lower in the presence of metastases (p = 0.013) and poorly
differentiated OC in patients responding to therapy (p = 0.016). Afamin
≥ 48.0 mg/L was also associated with a lower hazard ratio for recurrent
disease as compared to afamin < 48.0 mg/L (p = 0.007).
Post-therapeutic afamin ≥ 48 mg/L was positively correlated with overall
(p < 0.001) and progression-free (p = 0.012) survival and was lower
in non-responders than in responders (p = 0.048). Thus, afamin returned
post-therapeutically to values of healthy controls in responders
(p < 0.001) but not in non-responders (p = 0.114). Afamin in tumor
lysates was lower in poorly differentiated OC than in G 1 + 2 tumors
(p = 0.041). Higher afamin concentrations in tumor lysates were
associated with increased overall survival (p = 0.003).
Conclusion
These data indicate that afamin is associated with therapy response and survival rate in advanced OC patients.
Highlights
►
The plasma protein afamin is evaluated as prognostic tumor marker for
ovarian cancer
► Afamin plasma concentrations are associated with response to therapy and survival
► Afamin may therefore serve as therapy monitoring for estimation of disease progression
► Afamin plasma concentrations are associated with response to therapy and survival
► Afamin may therefore serve as therapy monitoring for estimation of disease progression
Canadians are ready for an adult conversation on Medicare
"This story is frequently told and easily understood. But it's almost completely false......
Canadians are ready for an adult conversation on Medicare
Canada's health-care system is ticking along nicely, Dr. Michael Rachlis says.Dreamstime Over the past two years, Brian Mulroney, former Bank of Canada governor David Dodge and other prominent Canadians have...
Published: Today at 4:00 PM
This article was sent from thestar.com mobile app.
Canada's health-care system is ticking along nicely, Dr. Michael Rachlis says.Dreamstime
Over the past two years, Brian Mulroney, former Bank of Canada governor David Dodge and other prominent Canadians have called for an "adult conversation on medicare." This month Globe and Mail columnist Jeffrey Simpson became the latest member of the Canadian chattering class to call for a mature deliberation about Canada's favourite social program.The analysis usually proceeds from a 30-second case for medicare's unaffordability. Medicare might have been well-meant but health costs are rising faster than government revenues and the economy. Governments can't fix medicare's problems without raising taxes, which isn't an option. The only hope is that Canadians will finally have a grown-up conversation about medicare and at least introduce more for-profit care if not dismantle it entirely.
This story is frequently told and easily understood. But it's almost completely false.
Total health-care costs as a share of the economy did rise when the economy tanked in 2008-9 but they have been falling for two years. For the past two years, provincial government health costs have also fallen as a share of GDP and as a share of their overall spending. Far from hitting the forecast 70 per cent, or even 50 per cent of program expenditures, provincial health costs are less than 38 per cent of program spending and falling.
Health care did grow from 33 per cent of program spending in the 1990s to 39 per cent in 2003 but this wasn't so much due to higher health costs as it was due to government cuts to other portfolios. From 2000 to 2011, Canadian governments cut taxes by nearly 6 per cent of GDP amounting to foregone annual revenue of $100 billion. And, contrary to the Canadian chin-wag consensus, Canadians strongly support higher progressive taxes. A spring Forum Institute poll indicated that Ontarians favoured by four to one raising higher earners' income taxes. Even Conservative voters favoured fair taxes by two to one.
But the good news is medicare doesn't need much if any new money or for-profit care. Many examples across the country demonstrate we could almost eliminate waits for doctors and other services through process improvement and system redesign. But Simpson and others seeking the mythical adult discussion hardly mention public sector options. These grownups are either ignorant about Etobicoke's Queensway surgicentre — North America's largest ambulatory surgical facility — or they want to keep us ignorant. The Queensway is part of the Trillium health system, a public hospital.
Unfortunately, medicare's real story doesn't get much air time. Former Saskatchewan premier Tommy Douglas talked all his life about the need for the second stage of medicare. He said the first stage featured public payment for the old system based on treating illness with doctors and hospitals. He said the second stage would highlight a redesigned delivery system focussed on keeping people healthy.
In the 1960s, Douglas and Supreme Court judge and co-founder of medicare Emmett Hall supported salaried doctors working in interdisciplinary teams. However, Douglas maintained that it was too politically difficult to change the way doctors were paid and how they did their work coincidently with pressuring them into public payment. For the rest of his life, he repeatedly warned that if the delivery system was left unreformed, medicare would increasingly fail Canadians and lose political support.
When Canadians hear about the second stage of medicare, they are more than ready for a mature conversation. When they hear about innovations to reduce wait lists, they are ready to eradicate them with public sector solutions. When they hear that public finance is more efficient and that Canadian taxes have been cut by $100 billion, they are ready for medicare to cover drugs and continuing care.
So let's start the grown-up conversation with a real question about access. Best practices across Canada demonstrate that we could see our family doctors within one day, see specialists within one week, and get elective surgery within three months. And we could get this much better care for little or no additional cost. How can we make this happen within the next two years everywhere in this country?
It's true that this won't be an easy. But it's a miracle we got medicare at all. The medical profession, almost all the provinces, and most of the Canadian elite opposed medicare 50 years ago. Fortunately, the Canadian people strongly supported medicare then and they still do. Let's plug into that good will and modernize our health system for the 21st century.
Dr. Michael Rachlis is a health policy analyst and an associate professor at the University of Toronto. www.michaelrachlis.ca
View Comments
Sent from my iPhone
Subscribe to:
Posts
(
Atom
)